Bioequivalence and Safety Evaluation of Imatinib mesylate Tablets in Patients of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Loading...
Date
item.page.authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The current study was designed to characterize the pharmacokinetic profile and to assess
newlinebioequivalence of the sponsor s Test formulation (Imatinib mesylate 400 mg tablets) with
newlineReference Listed product (Gleevec® 400 mg tablets, Novartis Pharmaceuticals) under
newlineFed conditions, in adult patients of Philadelphia chromosome positive Chronic Myeloid
newlineLeukemia (Ph+ CML) stabilized on Imatinib mesylate 400 mg. In addition, study was
newlineaimed to monitor safety profile of Investigational Medicinal Products (IMPs).
newlineit The study has concluded that Test product Imatinib mesylate 400mg tablets
newlinemanufactured for Ranbaxy Laboratories Limited, India is bioequivalent and safe, and can be used interchangeably in clinical practice.
newline